Welcome to our dedicated page for Artiva Biotherapeutics SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Laura Stoppel, Director at Artiva Biotherapeutics (ARTV), received a stock option grant on June 24, 2025. The grant consists of 13,750 options to purchase common stock at an exercise price of $1.61 per share. The options will fully vest on the earlier of June 24, 2026, or the date of the company's 2026 annual stockholder meeting.
Notable disclosure: Under an arrangement with RA Capital Management, Stoppel holds these options for the benefit of multiple funds: R.A. Capital Healthcare Fund, R.A. Capital Nexus Fund, Nexus Fund III, and a separately managed account. She must turn over any proceeds from exercise to RA Capital Management to offset advisory fees, and therefore disclaims beneficial ownership of both the options and underlying common stock.
The options have a ten-year term, expiring on June 23, 2035. This Form 4 was filed via attorney-in-fact Neha Krishnamohan on June 26, 2025.
Artiva Biotherapeutics Director Gines Diego Miralles received a stock option grant on June 24, 2025, as reported in this Form 4 filing. The derivative securities transaction details include:
- Grant of 13,750 stock options to purchase common stock
- Exercise price set at $1.61 per share
- Options expire on June 23, 2035
- Full vesting occurs on the earlier of June 24, 2026, or the date of the company's 2026 annual stockholder meeting
The filing was executed by Neha Krishnamohan as attorney-in-fact on June 26, 2025. This transaction represents a standard director compensation equity grant, with Miralles holding direct ownership of these derivative securities.
Director Brian Daniels of Artiva Biotherapeutics was granted stock options on June 24, 2025. The key details of this insider transaction include:
- Received 13,750 stock options to purchase common stock
- Exercise price set at $1.61 per share
- Options will expire on June 23, 2035
- Vesting schedule: 100% vesting on the earlier of June 24, 2026, or the date of the 2026 annual stockholder meeting
This grant appears to be part of the company's director compensation program. The transaction was reported via Form 4 filing and executed through an attorney-in-fact, Neha Krishnamohan. The options represent a new position for the director, as no prior holdings were reported in the filing.